Buy Q32 Bio Ahead of Bempikibart Push and Mid-2026 Data Window
Q32 Bio (QTTB) is a clinical-stage biotech focused on immune rebalancing through IL-7/TSLP receptor and complement programs. With a market cap near $200M, a lean balance sheet, and an upcoming mid-2026 data cadence tied to bempikibart advancement, we rate QTTB Buy. Our trade plan: enter at $11.81, stop $9.00, target $22.00 over a long-term horizon …